



US009102649B1

(12) **United States Patent**
Kandula

(10) **Patent No.:** **US 9,102,649 B1**

(45) **Date of Patent:** **Aug. 11, 2015**

(54) **COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS**

(71) Applicant: **Mahesh Kandula**, Andhra Pradesh (IN)

(72) Inventor: **Mahesh Kandula**, Andhra Pradesh (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/556,443**

(22) Filed: **Dec. 1, 2014**

(30) **Foreign Application Priority Data**

Sep. 29, 2014 (IN) 4873/CHE/2014
Nov. 20, 2014 (IN) PCT/IN2014/000726

(51) **Int. Cl.**
A61K 8/37 (2006.01)
C07C 57/03 (2006.01)
C07D 317/30 (2006.01)
C07C 69/593 (2006.01)
C07C 69/732 (2006.01)
C07C 69/73 (2006.01)

(52) **U.S. Cl.**
CPC **C07D 317/30** (2013.01); **C07C 69/593** (2013.01); **C07C 69/73** (2013.01); **C07C 69/732** (2013.01)

(58) **Field of Classification Search**
CPC A61Q 5/02
USPC 514/75, 114, 513
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,807,644 A 9/1957 Moore et al.
4,011,342 A 3/1977 Schwartz et al.
4,404,366 A 9/1983 Boguslaski et al.
4,412,992 A 11/1983 Chan
4,440,763 A 4/1984 Lover
4,550,109 A 10/1985 Folkers et al.
4,564,628 A 1/1986 Horn
4,778,794 A 10/1988 Naruse et al.
4,873,259 A 10/1989 Summers, Jr. et al.
4,920,122 A 4/1990 Naruse et al.
4,963,590 A 10/1990 Backstrom et al.
5,013,727 A 5/1991 Halskov
5,104,887 A 4/1992 Schoenwald et al.
5,120,738 A 6/1992 Ikawa et al.
5,149,695 A * 9/1992 Speiser et al. 514/75
5,242,937 A 9/1993 Pierce, Jr.
5,352,703 A 10/1994 Quadro
5,451,667 A * 9/1995 Speiser et al. 536/4.1
5,719,168 A 2/1998 Laurent
5,830,907 A 11/1998 Doble et al.
5,886,001 A 3/1999 Schmidhammer
6,156,777 A 12/2000 Hall et al.
6,414,008 B1 7/2002 Haul et al.
6,602,915 B2 8/2003 Uhrich
6,610,708 B1 8/2003 Asai et al.
6,613,802 B1 9/2003 Luskey et al.
7,101,912 B2 9/2006 Xiang et al.
7,544,834 B2 6/2009 Sumikawa et al.
7,645,767 B2 1/2010 Singh et al.

7,910,568 B2 3/2011 Wallace et al.
8,025,897 B2 9/2011 Bunick et al.
8,778,991 B2 7/2014 Gangakhedkar et al.
2003/0139437 A1 7/2003 Dobrozsi et al.
2003/0220468 A1 11/2003 Lai et al.
2003/0232867 A1 12/2003 Kobayashi et al.
2004/0010038 A1 1/2004 Blaugrund et al.
2004/0048924 A1 3/2004 Bunick et al.
2004/0106576 A1 6/2004 Jerussi et al.
2004/0170680 A1 9/2004 Oshlack et al.
2004/0215004 A1 10/2004 Berkner et al.
2004/0259953 A1 12/2004 Deregnaucourt et al.
2005/0020665 A1 1/2005 Neu
2005/0106248 A1 5/2005 Dixit et al.
2005/0244486 A1 11/2005 Caldwell et al.
2006/0014837 A1 1/2006 Deregnaucourt et al.
2006/0057644 A1 3/2006 Kelly et al.
2006/0058373 A1 3/2006 Abdel-Magid et al.
2006/0142566 A1 6/2006 Mathes et al.
2006/0270635 A1 11/2006 Wallace et al.
2006/0270706 A1 11/2006 Kimura et al.
2007/0259930 A1 11/2007 Bozik et al.
2008/0020996 A1 1/2008 Singh et al.
2008/0058362 A1 3/2008 Singh et al.
2008/0064743 A1 3/2008 Shah et al.
2008/0132578 A1 6/2008 Jerussi et al.
2008/0207564 A1 8/2008 Wallace et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 1199916 A1 1/1986
CN 1224610 A 8/1999
CN 1300213 A 6/2001
CN 1672678 A 9/2005
CN 1706813 A 12/2005

(Continued)

OTHER PUBLICATIONS

Schafer et al. Drug Discovery Today, 2008, 13 21-22, 913-916.*
Horig et al. Journal of Translational Medicine 2004, 2, 44.*
"Amidines and related compounds. 6. Studies on structure-activity relationships of antihypertensive and antisecretory agents related to clonidine", US National Library of Medicine National Institutes of HealthSearch database, Jan. 1975, by Jen T et al. (p. 1) <http://www.ncbi.nlm.nih.gov/pubmed/234014?report=abstract>.

(Continued)

Primary Examiner — Yong Chu
Assistant Examiner — Ana Z Muresan
(74) *Attorney, Agent, or Firm* — Raj Abhyanker, P.C.

(57) **ABSTRACT**

The present invention relates to compounds of Formula I and Formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of Formula I and Formula II; and formulated to treat an underlying etiology by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

6 Claims, 2 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0221111	A1	9/2008	Hesslinger et al.
2008/0227985	A1	9/2008	Raje et al.
2008/0262053	A1	10/2008	Reess
2008/0269166	A2	10/2008	Jerussi et al.
2008/0280936	A1	11/2008	Tung
2008/0319222	A1	12/2008	Sutton
2009/0075942	A1	3/2009	Czarnik
2009/0118365	A1	5/2009	Benson, III et al.
2009/0131535	A1	5/2009	Blaugrund et al.
2009/0326062	A1	12/2009	Palomo Nicolau et al.
2010/0004255	A1	1/2010	Belardinelli et al.
2010/0016328	A1	1/2010	Kakkis et al.
2010/0081713	A1	4/2010	Sharma et al.
2010/0316712	A1	12/2010	Nangia et al.
2011/0021628	A1	1/2011	Estrada et al.
2011/0087028	A1	4/2011	Hwang et al.
2011/0165234	A1	7/2011	Dixit et al.
2011/0172240	A1	7/2011	Milne et al.
2011/0218180	A1	9/2011	Singh et al.
2011/0229561	A1	9/2011	Kapoor et al.
2011/0230514	A1	9/2011	Tung
2011/0300190	A1	12/2011	Kandula
2011/0313036	A1	12/2011	Estrada et al.
2011/0313176	A1	12/2011	Khunt et al.
2012/0021046	A1	1/2012	Capomacchia et al.
2012/0022072	A1	1/2012	Kakkis et al.
2012/0046272	A1	2/2012	Sesha
2012/0093922	A1	4/2012	Manku et al.
2012/0095003	A1	4/2012	Gangakhedkar et al.
2012/0115817	A1	5/2012	Dos Santos et al.
2012/0157523	A1	6/2012	Gangakhedkar et al.
2012/0208850	A1	8/2012	Kong et al.
2012/0302794	A1	11/2012	Jerussi et al.
2013/0065909	A1	3/2013	Milne et al.
2013/0190327	A1	7/2013	Milne et al.
2013/0217737	A1	8/2013	Hasse et al.
2013/0267605	A1	10/2013	Scheuring et al.
2014/0080815	A1	3/2014	Wilhelm-Ogunbiyi et al.
2014/0100372	A1	4/2014	Raje et al.
2014/0134753	A1	5/2014	Kelly et al.
2014/0155455	A1	6/2014	Osterloh et al.
2014/0228389	A1	8/2014	Shah et al.
2014/0235710	A1	8/2014	Estrada et al.

FOREIGN PATENT DOCUMENTS

CN	1248690	C	4/2006
CN	1897935	A	1/2007
CN	101023056	A	8/2007
CN	101186583	A	5/2008
CN	101202326	A	6/2008
CN	101208326	A	6/2008
CN	100448852	C	1/2009
CN	101390854	A	3/2009
CN	100548300	C	10/2009
CN	101569618	A	11/2009
CN	101717392	A	6/2010
CN	101724934	A	6/2010
CN	101921245	A	12/2010
CN	102002053	A	4/2011
CN	102123763	A	7/2011
CN	102149673	A	8/2011
CN	102336767	A	2/2012
CN	102633799	A	8/2012
CN	102050815	B	4/2014
EP	0141393	A2	5/1985
EP	0150787	A2	8/1985
EP	0421441	A2	4/1991
EP	0934928	A1	8/1999
EP	1063230	A1	12/2000
EP	1695962	A1	8/2006
EP	1870395	A1	12/2007

EP	1889835	A1	2/2008
EP	1997493	A1	12/2008
EP	2298777	A2	3/2011
EP	2450039	A1	5/2012
FR	2722199	A1	1/1996
GB	1014020	A	12/1965
GB	1356470	A	6/1974
GB	2116541	A	9/1983
JP	56077259	A	6/1981
JP	S6089474	A	5/1985
RU	2436772	C2	12/2011
WO	9114430	A1	10/1991
WO	9118865	A1	12/1991
WO	9305029	A1	3/1993
WO	9413298	A1	6/1994
WO	9522546	A1	8/1995
WO	9531464	A1	11/1995
WO	9822443	A1	5/1998
WO	9852556	A1	11/1998
WO	0041693	A2	7/2000
WO	0059851	A1	10/2000
WO	0122967	A1	4/2001
WO	0200167	A2	1/2002
WO	0234713	A1	5/2002
WO	02062332	A1	8/2002
WO	02087512	A2	11/2002
WO	03018004	A2	3/2003
WO	03030877	A1	4/2003
WO	03086391	A1	10/2003
WO	03087038	A1	10/2003
WO	03097656	A2	11/2003
WO	2004031155	A1	4/2004
WO	2004052841	A1	6/2004
WO	2004075886	A1	9/2004
WO	2004078769	A1	9/2004
WO	2005046575	A2	5/2005
WO	2005110381	A1	11/2005
WO	2005116086	A2	12/2005
WO	2006096996	A1	9/2006
WO	2006120176	A2	11/2006
WO	2006125293	A1	11/2006
WO	2007086493	A1	8/2007
WO	2007121188	A2	10/2007
WO	2008030567	A2	3/2008
WO	2008074033	A1	6/2008
WO	2008079404	A2	7/2008
WO	2008089008	A2	7/2008
WO	2008098960	A1	8/2008
WO	2008137474	A1	11/2008
WO	2009002297	A1	12/2008
WO	2009056791	A1	5/2009
WO	2009061934	A1	5/2009
WO	2008113056	A2	8/2009
WO	2010020969	A1	2/2010
WO	2010115252	A1	10/2010
WO	2010127099	A2	11/2010
WO	2010147666	A1	12/2010
WO	2011017800	A1	2/2011
WO	2011060945	A2	5/2011
WO	2011085211	A1	7/2011
WO	2011089216	A1	7/2011
WO	2011106688	A1	9/2011
WO	2011154833	A1	12/2011
WO	2012007352	A1	1/2012
WO	2012025213	A2	3/2012
WO	2012027543	A1	3/2012
WO	2012055567	A2	5/2012
WO	2012115695	A1	8/2012
WO	2013008182	A1	1/2013
WO	2013017974	A1	2/2013
WO	2013024376	A1	2/2013
WO	2013027150	A1	2/2013
WO	2013152608	A1	10/2013
WO	2013167988	A1	11/2013
WO	2013167993	A1	11/2013
WO	2013167996	A1	11/2013

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO 2013168022 A1 11/2013
 WO 2013175377 A2 11/2013

OTHER PUBLICATIONS

“Progress Application of Fumaric Acid and the Derivatives of Fumaric Acid, Guangdong Chemical Industry”, Guangdong Chemical Industry, Jul. 31, 2007, by Gao Cuiying et al. (p. 1) http://en.cnki.com.cn/Article_en/CJFDTOTAL-GDHG200707027.htm.

“¹H and ¹³C Nuclear Magnetic Resonance Studies on the Tautomerism, Geometrical Isomerism and Conformation of some Cyclic Amidines, Guanidines and Related Systems”, Journal of American Chemical Society, May 1975, by Lloyd M. Jackman et al. (p. 1) <http://pubs.acs.org/doi/pdf/10.1021/ja00843a033>.

“Enzyme-catalyzed regioselective synthesis of lipophilic guaifenesin ester derivatives”, Journal of Molecular Catalysis B: Enzymatic, Feb. 2, 2004, by Na Wang et al. (p. 1) <http://www.sciencedirect.com/science/article/pii/S1381117703002650>.

“Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α -lipoic acid on insulin resistance in the obese Zucker rat”, Metabolism, Oct. 10, 2008 by Elizabeth A. Muellenbach et al. (p. 1) <http://www.sciencedirect.com/science/article/pii/S0026049508002047>.

“Effect of pentoxifylline and/or alpha lipoic acid on experimentally induced acute pancreatitis”, European Journal of Pharmacology, Jun. 21, 2010 by Amany A. Abdin et al. (p. 1) <http://www.ncbi.nlm.nih.gov/pubmed/20599924>.

“Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury”, Renal Failure, Feb. 27,

2012, by Behjat Seifi et al. (p. 1) <http://www.ncbi.nlm.nih.gov/pubmed/22364443>.

Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery, Journal of Pharmaceutical Science, by Hea-Jeong Doh et al. May 2003 (p. 1) <http://onlinelibrary.wiley.com/doi/10.1002/jps.10353/abstract>.

Probing the skin permeation of fish oil EPA and ketoprofen 1. NMR spectroscopy and molecular modelling, International Journal of Pharmaceutics, by Christopher P. Thomas et al. Feb. 12, 2007 (pp. 2) <http://www.sciencedirect.com/science/article/pii/S0378517307001330>.

RN 67195-24-8 Registry Entered STN: Nov. 16, 1984 (pp. 2) <http://chem.sis.nlm.nih.gov/chemidplus/rn/67195-24-8>.

“Palladium-Catalyzed Direct Arylation of Benzoxazoles with Unactivated Simple Arenes”, Chemical Communications journal, Sep. 14, 2012, by Ge Wu et al. (pp. 84) <http://www.rsc.org/suppdata/cc/c2/c2cc34238c/c2cc3428c.pdf>.


“Tafamidis”, from Nature Review Drug Discovery 11, Mar. 2012 by Gerard Said et al. (pp. 2) <http://www.nature.com/nrd/journal/v11/n3/full/nrd3675.html>.

“The role of structural information in the discovery of direct thrombin and factor Xa inhibitors”, Trends in Pharmacological Sciences, vol. 33, Issue 5, Apr. 2012 (p. 1) [http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147\(12\)00036-3](http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(12)00036-3).

“Nicotinamide-substituted complexes as redox markers. 1. Synthesis and UV investigation of rhenium and technetium mixed-ligand systems”, Journal of Labelled Compounds, Jan. 1998 by T. Kniess et al. (p. 1) http://www.researchgate.net/publication/243806712_Nicotinamide-substituted_complexes_as_redox_markers_1.

* cited by examiner

FIGURE - 1



```

ADV-B-1053-18
CLX-GLY-D1-RMR-CFA
exp2 PROTON
SAMPLE PRESATURATION n
date Nov 7 2014 satmore n
solvent cdc13 wet n
file SPECIAL
SW ACQUISITION exp 0
temp not used
at 7205.4 gain
bp 2.288 gain not used
f1 32700 Hst 0.368
f2 4300 P20 10.000
f3 5.001 a1ra 10.000
f4
f5
f6
f7
f8
f9
f10
f11
f12
f13
f14
f15
f16
f17
f18
f19
f20
f21
f22
f23
f24
f25
f26
f27
f28
f29
f30
f31
f32
f33
f34
f35
f36
f37
f38
f39
f40
f41
f42
f43
f44
f45
f46
f47
f48
f49
f50
f51
f52
f53
f54
f55
f56
f57
f58
f59
f60
f61
f62
f63
f64
f65
f66
f67
f68
f69
f70
f71
f72
f73
f74
f75
f76
f77
f78
f79
f80
f81
f82
f83
f84
f85
f86
f87
f88
f89
f90
f91
f92
f93
f94
f95
f96
f97
f98
f99
f100
f101
f102
f103
f104
f105
f106
f107
f108
f109
f110
f111
f112
f113
f114
f115
f116
f117
f118
f119
f120
f121
f122
f123
f124
f125
f126
f127
f128
f129
f130
f131
f132
f133
f134
f135
f136
f137
f138
f139
f140
f141
f142
f143
f144
f145
f146
f147
f148
f149
f150
f151
f152
f153
f154
f155
f156
f157
f158
f159
f160
f161
f162
f163
f164
f165
f166
f167
f168
f169
f170
f171
f172
f173
f174
f175
f176
f177
f178
f179
f180
f181
f182
f183
f184
f185
f186
f187
f188
f189
f190
f191
f192
f193
f194
f195
f196
f197
f198
f199
f200
f201
f202
f203
f204
f205
f206
f207
f208
f209
f210
f211
f212
f213
f214
f215
f216
f217
f218
f219
f220
f221
f222
f223
f224
f225
f226
f227
f228
f229
f230
f231
f232
f233
f234
f235
f236
f237
f238
f239
f240
f241
f242
f243
f244
f245
f246
f247
f248
f249
f250
f251
f252
f253
f254
f255
f256
f257
f258
f259
f260
f261
f262
f263
f264
f265
f266
f267
f268
f269
f270
f271
f272
f273
f274
f275
f276
f277
f278
f279
f280
f281
f282
f283
f284
f285
f286
f287
f288
f289
f290
f291
f292
f293
f294
f295
f296
f297
f298
f299
f300
f301
f302
f303
f304
f305
f306
f307
f308
f309
f310
f311
f312
f313
f314
f315
f316
f317
f318
f319
f320
f321
f322
f323
f324
f325
f326
f327
f328
f329
f330
f331
f332
f333
f334
f335
f336
f337
f338
f339
f340
f341
f342
f343
f344
f345
f346
f347
f348
f349
f350
f351
f352
f353
f354
f355
f356
f357
f358
f359
f360
f361
f362
f363
f364
f365
f366
f367
f368
f369
f370
f371
f372
f373
f374
f375
f376
f377
f378
f379
f380
f381
f382
f383
f384
f385
f386
f387
f388
f389
f390
f391
f392
f393
f394
f395
f396
f397
f398
f399
f400
f401
f402
f403
f404
f405
f406
f407
f408
f409
f410
f411
f412
f413
f414
f415
f416
f417
f418
f419
f420
f421
f422
f423
f424
f425
f426
f427
f428
f429
f430
f431
f432
f433
f434
f435
f436
f437
f438
f439
f440
f441
f442
f443
f444
f445
f446
f447
f448
f449
f450
f451
f452
f453
f454
f455
f456
f457
f458
f459
f460
f461
f462
f463
f464
f465
f466
f467
f468
f469
f470
f471
f472
f473
f474
f475
f476
f477
f478
f479
f480
f481
f482
f483
f484
f485
f486
f487
f488
f489
f490
f491
f492
f493
f494
f495
f496
f497
f498
f499
f500
f501
f502
f503
f504
f505
f506
f507
f508
f509
f510
f511
f512
f513
f514
f515
f516
f517
f518
f519
f520
f521
f522
f523
f524
f525
f526
f527
f528
f529
f530
f531
f532
f533
f534
f535
f536
f537
f538
f539
f540
f541
f542
f543
f544
f545
f546
f547
f548
f549
f550
f551
f552
f553
f554
f555
f556
f557
f558
f559
f560
f561
f562
f563
f564
f565
f566
f567
f568
f569
f570
f571
f572
f573
f574
f575
f576
f577
f578
f579
f580
f581
f582
f583
f584
f585
f586
f587
f588
f589
f590
f591
f592
f593
f594
f595
f596
f597
f598
f599
f600
f601
f602
f603
f604
f605
f606
f607
f608
f609
f610
f611
f612
f613
f614
f615
f616
f617
f618
f619
f620
f621
f622
f623
f624
f625
f626
f627
f628
f629
f630
f631
f632
f633
f634
f635
f636
f637
f638
f639
f640
f641
f642
f643
f644
f645
f646
f647
f648
f649
f650
f651
f652
f653
f654
f655
f656
f657
f658
f659
f660
f661
f662
f663
f664
f665
f666
f667
f668
f669
f670
f671
f672
f673
f674
f675
f676
f677
f678
f679
f680
f681
f682
f683
f684
f685
f686
f687
f688
f689
f690
f691
f692
f693
f694
f695
f696
f697
f698
f699
f700
f701
f702
f703
f704
f705
f706
f707
f708
f709
f710
f711
f712
f713
f714
f715
f716
f717
f718
f719
f720
f721
f722
f723
f724
f725
f726
f727
f728
f729
f730
f731
f732
f733
f734
f735
f736
f737
f738
f739
f740
f741
f742
f743
f744
f745
f746
f747
f748
f749
f750
f751
f752
f753
f754
f755
f756
f757
f758
f759
f760
f761
f762
f763
f764
f765
f766
f767
f768
f769
f770
f771
f772
f773
f774
f775
f776
f777
f778
f779
f780
f781
f782
f783
f784
f785
f786
f787
f788
f789
f790
f791
f792
f793
f794
f795
f796
f797
f798
f799
f800
f801
f802
f803
f804
f805
f806
f807
f808
f809
f810
f811
f812
f813
f814
f815
f816
f817
f818
f819
f820
f821
f822
f823
f824
f825
f826
f827
f828
f829
f830
f831
f832
f833
f834
f835
f836
f837
f838
f839
f840
f841
f842
f843
f844
f845
f846
f847
f848
f849
f850
f851
f852
f853
f854
f855
f856
f857
f858
f859
f860
f861
f862
f863
f864
f865
f866
f867
f868
f869
f870
f871
f872
f873
f874
f875
f876
f877
f878
f879
f880
f881
f882
f883
f884
f885
f886
f887
f888
f889
f890
f891
f892
f893
f894
f895
f896
f897
f898
f899
f900
f901
f902
f903
f904
f905
f906
f907
f908
f909
f910
f911
f912
f913
f914
f915
f916
f917
f918
f919
f920
f921
f922
f923
f924
f925
f926
f927
f928
f929
f930
f931
f932
f933
f934
f935
f936
f937
f938
f939
f940
f941
f942
f943
f944
f945
f946
f947
f948
f949
f950
f951
f952
f953
f954
f955
f956
f957
f958
f959
f960
f961
f962
f963
f964
f965
f966
f967
f968
f969
f970
f971
f972
f973
f974
f975
f976
f977
f978
f979
f980
f981
f982
f983
f984
f985
f986
f987
f988
f989
f990
f991
f992
f993
f994
f995
f996
f997
f998
f999

```


FIGURE - 2

ADV-B-1053-18
GLY-EPA-01-RMF ISOLATED
exp2 CARBON

```

SAMPLE PRESATURATION
date Nov 11 2014 satmode n
solvent cdc13 wet n
file SPECIAL
ACQUISITION exp SPECIAL
sw 25510.2 gain not used
at 1.285 spin not used
mp 65536 ht not used
fb 17000 pw90 9.200
hs 64 afra 10.000
al 1.000
nt 2000
ct TRANSMITTER 2000 in v 0
ln CL3 hs
sfrq 180.565 PROCESSING
tof 1531.1 fb 0.50
lprw 55 fn not used
pw 4.600 DISPLAY
DECOUPLER SP -588.3
dn H1 W9 18032.1
dof 0 rfl 1694.2
dm vxy ttp 0
dcwave w fd -102.7
dprw 41 lb -3.2
dmf 5564 PILOT
wc 180
sc 0
v5 133
th 4
nm cdc ph 4

```



1

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS

PRIORITY

The present application claims the benefit of PCT Application No. PCT/IN2014/000726 filed on Nov. 20, 2014, which further claims benefit of Indian Provisional Patent Application No. 4873/CHE/2014 filed on Sep. 29, 2014, the entire disclosure of which is relied on for all purposes and is incorporated into this application by reference.

FIELD OF THE INVENTION

This disclosure generally relates to compounds and compositions for the treatment of multiple sclerosis. More particularly, this invention relates to treating subjects with a pharmaceutically acceptable dose of compounds, stereoisomers, enantiomers, crystals, esters, salts, hydrates, prodrugs, or mixtures thereof.

BACKGROUND OF THE INVENTION

Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system. It generally strikes at an early age, most often the early adult years. Its most frequent symptoms include numbness, impaired vision, loss of balance, weakness, bladder dysfunction, and psychological changes. Fatigue is an early symptom in MS, often the earliest. The disease can wax and wane for up to 30 years, but in perhaps half of all cases it steadily progresses to severe disability and premature death.

MS is the most common cause of neurologic disability in young adults. The lesions of demyelination are histopathologically characteristic of the disease. Brain examination by MRI (magnetic resonance imaging) can accurately detect these "white matter plaques." MRI correlates well with the classic histopathology of the lesions, and is progressively a more sensitive tool for detecting the characteristic lesions of MS in situ, as compared to conventional functional evaluation. Multiple sclerosis is a complex disease, perhaps encompassing more than a single etiopathological entity and very likely subject to multifactorial etiology. MS prevalence worldwide is estimated at one million cases; in the United States this number is 250,000-350,000. Although not generally considered life threatening, this disease kills about 3,000 people each year in the United States.

The etiology of neurodegenerative diseases remains enigmatic; however, evidence for defects in energy metabolism, excitotoxicity, and for oxidative damage is increasingly compelling. It is likely that there is a complex interplay between these mechanisms. Mitochondria are the major intracellular source of free radicals, and increased mitochondrial calcium concentrations enhance free radical generation. Mitochondrial DNA is particularly susceptible to oxidative stress, and there is evidence of age-dependent damage and deterioration of respiratory enzyme activities with normal aging. This may contribute to the delayed onset and age dependence of neurodegenerative diseases. There is evidence for increased oxidative damage to macromolecules in amyotrophic lateral sclerosis, Multiple Sclerosis, Huntington's disease, Parkinson's disease, and Alzheimer's disease.

Inflammation is a self-defensive reaction aimed at eliminating or neutralizing injurious stimuli, and restoring tissue integrity. In neurodegenerative diseases inflammation occurs as a local response driven by microglia, in the absence of leukocyte infiltration. Like peripheral inflammation, neuroin-

2

flammation may become a harmful process, and it is now widely accepted that it may contribute to the pathogenesis of many central nervous system disorders, including chronic neurodegenerative diseases such as Multiple Sclerosis.


Managing acute pathology of often relies on the addressing underlying pathology and symptoms of the disease. There is currently a need in the art for new compositions to treatment or delay of the onset of multiple sclerosis and its associated complications progression.

SUMMARY OF THE INVENTION

The present invention provides compounds, compositions containing these compounds and methods for using the same to treat, prevent and/or ameliorate the effects of the conditions such as multiple sclerosis.


The invention herein provides compositions comprising of formula I or pharmaceutical acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one or more of pharmaceutically acceptable carriers, vehicles or diluents. These compositions may be used in the treatment of multiple sclerosis and its associated complications.

Formula I




In certain embodiments, the present invention relates to the compounds and compositions of formula I, or pharmaceutically acceptable salts thereof,

Formula I












Wherein,



R¹, R³ each independently represents —CH₃CO—, acetyl, D, H, CD₃CO—,








-continued



7



8



25


a is independently 2, 3 or 7;
 each b is independently 3, 5 or 6;
 e is independently 1, 2 or 6;

c and d are each independently H, D, —OH, —OD, C₁-C₆-alkyl, —NH₂ or —COCH₃.


Wherein
 R¹, R² each independently represents H, D,

The invention herein also provides compositions comprising of formula II or pharmaceutical acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula II or intermediates thereof and one or more of pharmaceutically acceptable carriers, vehicles or diluents. These compositions may be used in the treatment of multiple sclerosis and its associated complications.

Formula II




45




50

Accordingly, in certain embodiments, the present invention relates to the compounds and compositions of formula II, or pharmaceutically acceptable salts thereof,

Formula II




60




65

9


-continued




5


















10



20





25




10

-continued




15



or


20



R², R⁴ each independently represents D, CH₃CO, CD₃CO,

13



14



a is independently 2, 3 or 7;
 each b is independently 3, 5 or 6;
 e is independently 1, 2 or 6;
 c and d are each independently H, D, —OH, —OD, C₁-C₆-alkyl, —NH₂ or —COCH₃.


In the illustrative embodiments, examples of compounds of formula I are as set forth below:

The application also discloses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compositions herein. In some aspects, the pharmaceutical composition is formulated for systemic administration, oral administration, sustained release, parenteral administration, injection, subdermal administration, or transdermal administration.



In the illustrative embodiments, examples of compounds of formula II are as set forth below:

Herein, the application additionally provides kits comprising the pharmaceutical compositions described herein. The



Herein the application also provides a kit comprising any of the pharmaceutical compositions disclosed herein. The kit may comprise instructions for use in the treatment of multiple sclerosis or its related complications.

kits may further comprise instructions for use in the treatment of multiple sclerosis or its related complications. The compositions described herein have several uses. The present application provides, for example, methods of treat-

ing a patient suffering from multiple sclerosis or its related complications manifested from neurodegeneration, neurological dysfunction, metabolic conditions or disorders, metabolic syndrome, chronic diseases or disorders; Hyperinsulinemia, Insulin resistance, Glucose intolerance, Hepatology, Cancer, Respiratory, Hematological, Orthopedic, Cardiovascular, Renal, Skin, Nephrological, or Ocular complications.

BRIEF DESCRIPTION OF FIGURES

Example embodiments are illustrated by way of example and not limitation in the figures of the accompanying drawings, in which like references indicate similar elements and in which:

FIG. 1 shows the ¹H-NMR results for Formula II.

FIG. 2 shows the ¹³C-NMR results for Formula II.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art.

The compounds of the present invention can be present in the form of pharmaceutically acceptable salts. The compounds of the present invention can also be present in the form of pharmaceutically acceptable esters (i.e., the methyl and ethyl esters of the acids of formula I and formula II to be used as prodrugs). The compounds of the present invention can also be solvated, i.e. hydrated. The solvation can be affected in the course of the manufacturing process or can take place i.e. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I and formula II (hydration).

Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers." Diastereomers are stereoisomers with opposite configuration at one or more chiral centers which are not enantiomers. Stereoisomers bearing one or more asymmetric centers that are non-superimposable mirror images of each other are termed "enantiomers." When a compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center or centers and is described by the R- and S-sequencing rules of Cahn, Ingold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".

As used herein, the term "metabolic condition" refers to an Inborn errors of metabolism (or genetic metabolic conditions) are genetic disorders that result from a defect in one or more metabolic pathways; specifically, the function of an enzyme is affected and is either deficient or completely absent.

The term "polymorph" as used herein is art-recognized and refers to one crystal structure of a given compound.

The phrases "parenteral administration" and "administered parenterally" as used herein refer to modes of adminis-

tration other than enteral and topical administration, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradental, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

A "patient," "subject," or "host" to be treated by the subject method may mean either a human or non-human animal, such as primates, mammals, and vertebrates.

The phrase "pharmaceutically acceptable" is art-recognized. In certain embodiments, the term includes compositions, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase "pharmaceutically acceptable carrier" is art-recognized, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition, from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of a subject composition and not injurious to the patient. In certain embodiments, a pharmaceutically acceptable carrier is non-pyrogenic. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

The term "prodrug" is intended to encompass compounds that, under physiological conditions, are converted into the therapeutically active agents of the present invention. A common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal.

The term "prophylactic or therapeutic" treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).

The term "predicting" as used herein refers to assessing the probability related diseases patient will suffer from abnormalities or complication and/or terminal platelet aggregation

or failure and/or death (i.e. mortality) within a defined time window (predictive window) in the future. The mortality may be caused by the central nervous system or complication. The predictive window is an interval in which the subject will develop one or more of the said complications according to the predicted probability. The predictive window may be the entire remaining lifespan of the subject upon analysis by the method of the present invention.

The term "treating" is art-recognized and includes preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected, such as treating the neurological condition such as multiple sclerosis and other diseases related to oxidative stress such as renal diseases of a subject by administration of an agent even though such agent does not treat the cause of the condition. The term "treating", "treat" or "treatment" as used herein includes curative, preventative (e.g., prophylactic), adjunct and palliative treatment.

The phrase "therapeutically effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a salt or composition disclosed herein that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time. The effective amount may vary depending on such factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.

In certain embodiments, the pharmaceutical compositions described herein are formulated in a manner such that said compositions will be delivered to a patient in a therapeutically effective amount, as part of a prophylactic or therapeutic treatment. The desired amount of the composition to be administered to a patient will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the salts and compositions from the subject compositions. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.

Additionally, the optimal concentration and/or quantities or amounts of any particular salt or composition may be adjusted to accommodate variations in the treatment parameters. Such treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.

In certain embodiments, the dosage of the subject compositions provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum

plasma concentration (C_{max}) and the area under the plasma concentration-time curve from time 0 to infinity may be used.

When used with respect to a pharmaceutical composition or other material, the term "sustained release" is art-recognized. For example, a subject composition which releases a substance over time may exhibit sustained release characteristics, in contrast to a bolus type administration in which the entire amount of the substance is made biologically available at one time. For example, in particular embodiments, upon contact with body fluids including blood, spinal fluid, mucus secretions, lymph or the like, one or more of the pharmaceutically acceptable excipients may undergo gradual or delayed degradation (e.g., through hydrolysis) with concomitant release of any material incorporated therein, e.g., an therapeutic and/or biologically active salt and/or composition, for a sustained or extended period (as compared to the release from a bolus). This release may result in prolonged delivery of therapeutically effective amounts of any of the therapeutic agents disclosed herein.

The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" are art-recognized, and include the administration of a subject composition, therapeutic or other material at a site remote from the disease being treated. Administration of an agent for the disease being treated, even if the agent is subsequently distributed systemically, may be termed "local" or "topical" or "regional" administration, other than directly into the central nervous system, e.g., by subcutaneous administration, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.

The phrase "therapeutically effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a salt or composition disclosed herein that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time. The effective amount may vary depending on such factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.

The present disclosure also contemplates prodrugs of the compositions disclosed herein, as well as pharmaceutically acceptable salts of said prodrugs.

This application also discloses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of a compound of Formula I and formula II may be formulated for systemic or topical or oral administration. The pharmaceutical composition may be also formulated for oral administration, oral solution, injection, subdermal administration, or transdermal administration. The pharmaceutical composition may further comprise at least one of a pharmaceutically acceptable stabilizer, diluent, surfactant, filler, binder, and lubricant.

In many embodiments, the pharmaceutical compositions described herein will incorporate the disclosed compounds and compositions (Formula I and Formula II) to be delivered in an amount sufficient to deliver to a patient a therapeutically effective amount of a compound of formula I and formula II or composition as part of a prophylactic or therapeutic treatment. The desired concentration of formula I and formula II or its pharmaceutical acceptable salts will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the salts and compositions from the subject

compositions. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.

Additionally, the optimal concentration and/or quantities or amounts of any particular compound of formula I and formula II may be adjusted to accommodate variations in the treatment parameters. Such treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.

The concentration and/or amount of any compound of formula I and formula II may be readily identified by routine screening in animals, e.g., rats, by screening a range of concentration and/or amounts of the material in question using appropriate assays. Known methods are also available to assay local tissue concentrations, diffusion rates of the salts or compositions, and local blood flow before and after administration of therapeutic formulations disclosed herein. One such method is microdialysis, as reviewed by T. E. Robinson et al., 1991, microdialysis in the neurosciences, Techniques, volume 7, Chapter 1. The methods reviewed by Robinson may be applied, in brief, as follows. A microdialysis loop is placed in situ in a test animal. Dialysis fluid is pumped through the loop. When compounds with formula I and formula II such as those disclosed herein are injected adjacent to the loop, released drugs are collected in the dialysate in proportion to their local tissue concentrations. The progress of diffusion of the salts or compositions may be determined thereby with suitable calibration procedures using known concentrations of salts or compositions.

In certain embodiments, the dosage of the subject compounds of formula I and formula II provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum plasma concentration (C_{max}) and the area under the plasma concentration-time curve from time 0 to infinity may be used.

Generally, in carrying out the methods detailed in this application, an effective dosage for the compounds of Formulas I is in the range of about 0.01 mg/kg/day to about 100 mg/kg/day in single or divided doses, for instance 0.01 mg/kg/day to about 50 mg/kg/day in single or divided doses. The compounds of Formulas I may be administered at a dose of, for example, less than 0.2 mg/kg/day, 0.5 mg/kg/day, 1.0 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, or 40 mg/kg/day. Compounds of Formula I and formula II may also be administered to a human patient at a dose of, for example, between 0.1 mg and 1000 mg, between 5 mg and 80 mg, or less than 1.0, 9.0, 12.0, 20.0, 50.0, 75.0, 100, 300, 400, 500, 800, 1000, 2000, 5000 mg per day. In certain embodiments, the compositions herein are administered at an amount that is less than 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the compound of formula I and formula II required for the same therapeutic benefit.

An effective amount of the compounds of formula I and formula II described herein refers to the amount of one of said salts or compositions which is capable of inhibiting or preventing a disease.

An effective amount may be sufficient to prohibit, treat, alleviate, ameliorate, halt, restrain, slow or reverse the progression, or reduce the severity of a complication resulting

from nerve damage or demyelization and/or elevated reactive oxidative-nitrosative species and/or abnormalities in neurotransmitter homeostasis's, in patients who are at risk for such complications. As such, these methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate. The amount and timing of compositions administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. Thus, because of patient-to-patient variability, the dosages given above are a guideline and the physician may titrate doses of the drug to achieve the treatment that the physician considers appropriate for the patient. In considering the degree of treatment desired, the physician must balance a variety of factors such as age of the patient, presence of preexisting disease, as well as presence of other diseases.

The compositions provided by this application may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary. Further, the compositions may be administered intranasally, as a rectal suppository, or using a "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water. Furthermore, the compositions may be administered to a subject in need of treatment by controlled release dosage forms, site specific drug delivery, transdermal drug delivery, patch (active/passive) mediated drug delivery, by stereotactic injection, or in nanoparticles.

The compositions may be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses. Suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the compositions and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as L-arginine, sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrates such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Appropriate materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof. The compounds of formula I and formula II may also comprise enterically coated comprising of various excipients, as is well known in the pharmaceutical art.

For parenteral administration, solutions of the compositions may be prepared in (for example) sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed. Such aqueous solutions should be suitably buff-

ered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

The formulations, for instance tablets, may contain e.g. 10 to 100, 50 to 250, 150 to 500 mg, or 350 to 800 mg e.g. 10, 50, 100, 300, 500, 700, 800 mg of the compounds of formula I and formula II disclosed herein, for instance, compounds of formula I and formula II or pharmaceutical acceptable salts of a compounds of Formula I.

Generally, a composition as described herein may be administered orally, or parenterally (e.g., intravenous, intramuscular, subcutaneous or intramedullary). Topical administration may also be indicated, for example, where the patient is suffering from gastrointestinal disorder that prevent oral administration, or whenever the medication is best applied to the surface of a tissue or organ as determined by the attending physician. Localized administration may also be indicated, for example, when a high dose is desired at the target tissue or organ. For buccal administration the active composition may take the form of tablets or lozenges formulated in a conventional manner.

The dosage administered will be dependent upon the identity of the neurological disease; the type of host involved, including its age, health and weight; the kind of concurrent treatment, if any; the frequency of treatment and therapeutic ratio.

Illustratively, dosage levels of the administered active ingredients are: intravenous, 0.1 to about 200 mg/kg; intramuscular, 1 to about 500 mg/kg; orally, 5 to about 1000 mg/kg; intranasal instillation, 5 to about 1000 mg/kg; and aerosol, 5 to about 1000 mg/kg of host body weight.

Expressed in terms of concentration, an active ingredient can be present in the compositions of the present invention for localized use about the cutis, intranasally, pharyngolaryngeally, bronchially, intravaginally, rectally, or ocularly in a concentration of from about 0.01 to about 50% w/w of the composition; preferably about 1 to about 20% w/w of the composition; and for parenteral use in a concentration of from about 0.05 to about 50% w/v of the composition and preferably from about 5 to about 20% w/v.

The compositions of the present invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenteral solutions of suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient. For oral administration either solid or fluid unit dosage forms can be prepared.

As discussed above, the tablet core contains one or more hydrophilic polymers. Suitable hydrophilic polymers include, but are not limited to, water swellable cellulose derivatives, polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, swelling cross-linked polymers, and mixtures thereof. Examples of suitable water swellable cellulose derivatives include, but are not limited to, sodium carboxymethylcellulose, cross-linked hydroxypropylcellulose, hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylcellulose, hydroxybutylcellulose, hydroxyphenylcellulose, hydroxyethylcellulose (HEC), hydroxypentylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylethylcellulose, and mixtures thereof. Examples of suitable poly-

alkylene glycols include, but are not limited to, polyethylene glycol. Examples of suitable thermoplastic polyalkylene oxides include, but are not limited to, poly(ethylene oxide). Examples of suitable acrylic polymers include, but are not limited to, potassium methacrylatedivinylbenzene copolymer, polymethylmethacrylate, high-molecular weight crosslinked acrylic acid homopolymers and copolymers such as those commercially available from Noveon Chemicals under the tradename CARBOPOL™. Examples of suitable hydrocolloids include, but are not limited to, alginates, agar, guar gum, locust bean gum, kappa carrageenan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gellan gum, maltodextrin, galactomannan, pustulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, and mixtures thereof. Examples of suitable clays include, but are not limited to, smectites such as bentonite, kaolin, and laponite; magnesium trisilicate; magnesium aluminum silicate; and mixtures thereof. Examples of suitable gelling starches include, but are not limited to, acid hydrolyzed starches, swelling starches such as sodium starch glycolate and derivatives thereof, and mixtures thereof. Examples of suitable swelling cross-linked polymers include, but are not limited to, cross-linked polyvinyl pyrrolidone, cross-linked agar, and cross-linked carboxymethylcellulose sodium, and mixtures thereof.

The carrier may contain one or more suitable excipients for the formulation of tablets. Examples of suitable excipients include, but are not limited to, fillers, adsorbents, binders, disintegrants, lubricants, glidants, release-modifying excipients, superdisintegrants, antioxidants, and mixtures thereof.

Suitable binders include, but are not limited to, dry binders such as polyvinyl pyrrolidone and hydroxypropylmethylcellulose; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arabic, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pustulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, celluloses, sucrose, and starches; and mixtures thereof. Suitable disintegrants include, but are not limited to, sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and mixtures thereof.

Suitable lubricants include, but are not limited to, long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides waxes, and mixtures thereof. Suitable glidants include, but are not limited to, colloidal silicon dioxide. Suitable release-modifying excipients include, but are not limited to, insoluble edible materials, pH-dependent polymers, and mixtures thereof.

Suitable insoluble edible materials for use as release-modifying excipients include, but are not limited to, water-insoluble polymers and low-melting hydrophobic materials, copolymers thereof, and mixtures thereof. Examples of suitable water-insoluble polymers include, but are not limited to, ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, copolymers thereof, and mixtures thereof. Suitable low-melting hydrophobic materials include, but are not limited to, fats, fatty acid esters, phospholipids, waxes, and mixtures thereof. Examples of suitable fats include, but are not limited to, hydrogenated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil, free fatty acids

and their salts, and mixtures thereof. Examples of suitable fatty acid esters include, but are not limited to, sucrose fatty acid esters, mono-, di-, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, Glyco-Wax-932, lauroyl macrogol-32 glycerides, stearyl macrogol-32 glycerides, and mixtures thereof. Examples of suitable phospholipids include phosphotidyl choline, phosphotidyl serene, phosphotidyl enositol, phosphotidic acid, and mixtures thereof. Examples of suitable waxes include, but are not limited to, carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate, and mixtures thereof. Examples of super disintegrants include, but are not limited to, croscarmellose sodium, sodium starch glycolate and cross-linked povidone (crospovidone). In one embodiment the tablet core contains up to about 5 percent by weight of such super disintegrant.

Examples of antioxidants include, but are not limited to, tocopherols, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid, and edetate salts, and mixtures thereof. Examples of preservatives include, but are not limited to, citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid, and mixtures thereof.

In one embodiment, the immediate release coating has an average thickness of at least 50 microns, such as from about 50 microns to about 2500 microns; e.g., from about 250 microns to about 1000 microns. In embodiment, the immediate release coating is typically compressed at a density of more than about 0.9 g/cc, as measured by the weight and volume of that specific layer.

In one embodiment, the immediate release coating contains a first portion and a second portion, wherein at least one of the portions contains the second pharmaceutically active agent. In one embodiment, the portions contact each other at a center axis of the tablet. In one embodiment, the first portion includes the first pharmaceutically active agent and the second portion includes the second pharmaceutically active agent.

In one embodiment, the first portion contains the first pharmaceutically active agent and the second portion contains the second pharmaceutically active agent. In one embodiment, one of the portions contains a third pharmaceutically active agent. In one embodiment one of the portions contains a second immediate release portion of the same pharmaceutically active agent as that contained in the tablet core.

In one embodiment, the outer coating portion is prepared as a dry blend of materials prior to addition to the coated tablet core. In another embodiment the outer coating portion is included of a dried granulation including the pharmaceutically active agent.

Formulations with different drug release mechanisms described above could be combined in a final dosage form containing single or multiple units. Examples of multiple units include multilayer tablets, capsules containing tablets, beads, or granules in a solid or liquid form. Typical, immediate release formulations include compressed tablets, gels, films, coatings, liquids and particles that can be encapsulated, for example, in a gelatin capsule. Many methods for preparing coatings, covering or incorporating drugs, are known in the art.

The immediate release dosage, unit of the dosage form, i.e., a tablet, a plurality of drug-containing beads, granules or particles, or an outer layer of a coated core dosage form, contains a therapeutically effective quantity of the active agent with conventional pharmaceutical excipients. The immediate release dosage unit may or may not be coated, and may or may not be admixed with the delayed release dosage

unit or units (as in an encapsulated mixture of immediate release drug-containing granules, particles or beads and delayed release drug-containing granules or beads).

Extended release formulations are generally prepared as diffusion or osmotic systems, for example, as described in "Remington—The Science and Practice of Pharmacy", 20th. Ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000). A diffusion system typically consists of one of two types of devices, reservoir and matrix, which are well known and described in die art. The matrix devices are generally prepared by compressing the drug with a slowly dissolving polymer carrier into a tablet form.

An immediate release portion can be added to the extended release system by means of either applying an immediate release layer on top of the extended release core; using coating or compression processes or in a multiple unit system such as a capsule containing extended and immediate release beads.

Delayed release dosage formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in the acid environment of the stomach, but soluble in the neutral environment of small intestines. The delayed release dosage units can be prepared, for example, by coating a drug or a drug-containing composition with a selected coating material. The drug-containing composition may be a tablet for incorporation into a capsule, a tablet for use as an inner core in a "coated core" dosage form, or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or capsule.

A pulsed release dosage form is one that mimics a multiple dosing profile without repeated dosing and typically allows at least a twofold reduction in dosing frequency as compared to the drug presented as a conventional dosage form (e.g., as a solution or prompt drug-releasing, conventional solid dosage form). A pulsed release profile is characterized by a time period of no release (lag time) or reduced release followed by rapid drug release.

Each dosage form contains a therapeutically effective amount of active agent. In one embodiment of dosage forms that mimic a twice daily dosing profile, approximately 30 wt. % to 70 wt. %, preferably 40 wt. % to 60 wt. %, of the total amount of active agent in the dosage form is released in the initial pulse, and, correspondingly approximately 70 wt. % to 3.0 wt. %, preferably 60 wt. % to 40 wt. %, of the total amount of active agent in the dosage form is released in the second pulse. For dosage forms mimicking the twice daily dosing profile, the second pulse is preferably released approximately 3 hours to less than 14 hours, and more preferably approximately 5 hours to 12 hours, following administration.

Another dosage form contains a compressed tablet or a capsule having a drug-containing immediate release dosage unit, a delayed release dosage unit and an optional second delayed release dosage unit. In this dosage form, the immediate release dosage unit contains a plurality of beads, granules particles that release drug substantially immediately following oral administration to provide an initial dose. The delayed release dosage unit contains a plurality of coated beads or granules, which release drug approximately 3 hours to 14 hours following oral administration to provide a second dose.

For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, may be prepared.

Methods of preparing various pharmaceutical compositions with a certain amount of one or more compounds of formula I and formula II or other active agents are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceuti-

cal compositions, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995).

In addition, in certain embodiments, subject compositions of the present application may be lyophilized or subjected to another appropriate drying technique such as spray drying. The subject compositions may be administered once, or may be divided into a number of smaller doses to be administered at varying intervals of time, depending in part on the release rate of the compositions and the desired dosage.

Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of a subject composition which may be combined with a carrier material to produce a single dose may vary depending upon the subject being treated, and the particular mode of administration.

Methods of preparing these formulations or compositions include the step of bringing into association subject compositions with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a subject composition with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

The compounds of formula I and formula II described herein may be administered in inhalant or aerosol formulations. The inhalant or aerosol formulations may comprise one or more agents, such as adjuvants, diagnostic agents, imaging agents, or therapeutic agents useful in inhalation therapy. The final aerosol formulation may for example contain 0.005-90% w/w, for instance 0.005-50%, 0.005-5% w/w, or 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.

In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject compositions, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, corn, peanut, sunflower, soybean, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Suspensions, in addition to the subject compositions, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the encapsulated compound(s) and composition(s). Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing such carriers as are known in the art to be appropriate.

Dosage forms for transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. A subject composition may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required. For transdermal administration, the complexes may include lipophilic and hydrophilic groups to achieve the desired water solubility and transport properties.

The ointments, pastes, creams and gels may contain, in addition to subject compositions, other carriers, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of such substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

Methods of delivering a composition or compositions via a transdermal patch are known in the art. Exemplary patches and methods of patch delivery are described in U.S. Pat. Nos. 6,974,588, 6,564,093, 6,312,716, 6,440,454, 6,267,983, 6,239,180, and 6,103,275.

In another embodiment, a transdermal patch may comprise: a substrate sheet comprising a composite film formed of a resin composition comprising 100 parts by weight of a polyvinyl chloride-polyurethane composite and 2-10 parts by weight of a styrene-ethylene-butylene-styrene copolymer, a first adhesive layer on the one side of the composite film, and a polyalkylene terephthalate film adhered to the one side of the composite film by means of the first adhesive layer, a primer layer which comprises a saturated polyester resin and is formed on the surface of the polyalkylene terephthalate film; and a second adhesive layer comprising a styrene-diene-styrene block copolymer containing a pharmaceutical agent layered on the primer layer. A method for the manufacture of the above-mentioned substrate sheet comprises preparing the above resin composition molding the resin composition into a composite film by a calendar process, and then adhering a polyalkylene terephthalate film on one side of the composite film by means of an adhesive layer thereby forming the substrate sheet, and forming a primer layer comprising a saturated polyester resin on the outer surface of the polyalkylene terephthalate film.

Another type of patch comprises incorporating the drug directly in a pharmaceutically acceptable adhesive and laminating the drug-containing adhesive onto a suitable backing member, e.g. a polyester backing membrane. The drug should

27

be present at a concentration which will not affect the adhesive properties, and at the same time deliver the required clinical dose.


Transdermal patches may be passive or active. Passive transdermal drug delivery systems currently available, such as the nicotine, estrogen and nitroglycerine patches, deliver small-molecule drugs. Many of the newly developed proteins and peptide drugs are too large to be delivered through passive transdermal patches and may be delivered using technology such as electrical assist (iontophoresis) for large-molecule drugs.

Iontophoresis is a technique employed for enhancing the flux of ionized substances through membranes by application of electric current. One example of an iontophoretic membrane is given in U.S. Pat. No. 5,080,646 to Theeuwes. The principal mechanisms by which iontophoresis enhances molecular transport across the skin are (a) repelling a charged ion from an electrode of the same charge, (b) electroosmosis, the convective movement of solvent that occurs through a charged pore in response the preferential passage of counterions when an electric field is applied or (c) increase skin permeability due to application of electrical current.


In some cases, it may be desirable to administer in the form of a kit, it may comprise a container for containing the separate compositions such as a divided bottle or a divided foil packet. Typically the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a plastic material that may be transparent.

Methods and compositions for the treatment of multiple sclerosis. Among other things, herein is provided a method of treating multiple sclerosis, comprising administering to a patient in need thereof a therapeutically effective amount of compound of Formula I:




Wherein,
 R¹, R³ each independently represents —CH₃CO—, acetyl,
 D, H, CD₃CO—,



28























-continued



Formula I

5
10
15
20
25
30
35
40
45
50
55
60
65


29

R², R⁴ each independently represents H, D,

30


33

Wherein
 R^1, R^3 each independently represents H, D,




34

-continued




R^2, R^4 each independently represents D, CH_3CO , CD_3CO ,



35

36


-continued



37

38

-continued




a is independently 2, 3 or 7;
 each b is independently 3, 5 or 6;
 e is independently 1, 2 or 6;
 c and d are each independently H, D, —OH, —OD, C₁-C₆-alkyl, —NH₂ or —COCH₃.

30 Methods of Making

Examples of synthetic pathways useful for making compounds of formula II are set forth in example below and generalized in scheme 1:


Scheme-1:




39

40

-continued




Step-1: Synthesis of Compound 3:



To a solution of INT-1 (30 g, 0.22 mol), INT-2 (38 g, 0.29 mol), DMAP (26 g, 0.22 mol) in Dichloromethane (200 ml) was added drop wise the solution of DCC (50 g, 0.24 mol) in Dichloromethane (100 ml) under nitrogen atmosphere at 25° C. After the addition, reaction mixture was stirred for 2-3 h at 25° C. The Progress of reaction was monitored by TLC. Reaction mixture was filtered to remove DCU byproduct and bed washed with Dichloromethane (2×20 ml). The collected filtrate was washed with DM water (1×150 ml), 5% hydrochloric acid solution (1×50 ml), sat. Sodium bicarbonate solution (1×100 ml), washed with 10% brine solution (1×50 ml). The collected organic layer was dried (anh. Na₂SO₄) filtered and distilled off under reduced pressure at 40-45° C. The crude was dissolved in hexane (600 ml) filtered immediately to remove insoluble impurities (DCU). Collected filtrate was concentrated under reduced pressure to minimum volume (~50-100 ml). Filtered product and bed washed with hexane (2×50 ml), air dried product at 35-40° C. to afford INT-3 (40 g, 74%) as off white powder.

Step-2: Synthesis of Compound 4:




To a solution of INT-3 (20 g, 0.08 mol) in Dioxane (100 ml) was added drop wise 5N Hydrochloric acid (100 ml) at 25° C. The reaction mixture was stirred for 1 h at 25° C. and Progress of reaction was monitored by TLC. After starting material was consumed completely, the reaction mixture was neutralized by addition of solid sodium carbonate until pH was basic (~pH 8) and crude mass was filtered off to remove inorganic materials. The filtrate was concentrated under reduced pressure to remove dioxane and aqueous layer was extracted with Ethyl acetate (2×100 ml) and combined organic extracts were dried (Na₂SO₄), filtered and concentrated under reduced pressure at 40-45° C. The crude residue was stirred in diisopropyl ether (100 ml) for 4-6 h and the suspension was filtered. Isolated product was air dried at 40-50° C. to afford INT-4 (10 g, 60%) as off white solid.

41

42


Step-3: Synthesis of Compound 5:



To a solution of INT-4 (10 g, 0.04 mol), EPA (16.2 g, 0.05 mol), DMAP (2.9 g, 0.02 mol) in Dichloromethane (400 ml) was added the solution of DCC (10.9 g, 0.05 mol) in Dichloromethane (100 ml) under nitrogen atmosphere at 25° C. After the addition, reaction mixture was stirred for 1-2 h at 25° C. The progress of reaction was monitored by TLC. Reaction mixture was filtered to remove DCU byproduct and bed washed with Dichloromethane (2×25 ml). The collected filtrate was washed with DM water (1×150 ml), 5% hydro-

chloric acid solution (1×50 ml), sat. Sodium bicarbonate solution (1×100 ml), washed with 10% brine solution (1×50 ml). The organic layer was dried (Na₂SO₄), filtered and solvent was distilled off at reduced pressure at 40-45° C. The crude was purified by passing over silica gel column (60-120 mesh) by eluting with 15-20% Ethyl acetate:Hexane to afford INT-5 (11 g, 46%).

Step-4: Synthesis of Compound 6:



43

To a solution of INT-5 (11 g, 24 mmol), MMF (3.8 g, 29 mmol), DMAP (2.9 g, 24 mmol) in Dichloromethane (80 ml) was added the solution of DCC (4.9 g, 24 mmol) in Dichloromethane (30 ml) under nitrogen atmosphere at 25° C. After the addition, reaction mixture was stirred for 1-2 h at 25° C. The Progress of reaction was monitored by TLC. Reaction mixture was filtered to remove DCU byproduct and bed washed with Dichloromethane (2×15 ml). The collected filtrate was washed with DM water (1×100 ml), 5% hydrochloric acid solution (1×25 ml), sat. Sodium bicarbonate solution (1×25 ml), washed with 10% brine solution (1×25 ml). The organic layer was dried (Na₂SO₄), filtered and solvent was distilled off at reduced pressure at 40-45° C. The crude was purified by passing over silica gel column (60-120 mesh) by eluting with 10-13% Ethyl acetate:Hexane to afford final compound 6 (10 g, 73%).

The term "sample" refers to a sample of a body fluid, to a sample of separated cells or to a sample from a tissue or an organ. Samples of body fluids can be obtained by well-known techniques and include, preferably, samples of blood, plasma, serum, or urine, more preferably, samples of blood, plasma or serum. Tissue or organ samples may be obtained from any tissue or organ by, e.g., biopsy. Separated cells may be obtained from the body fluids or the tissues or organs by separating techniques such as centrifugation or cell sorting.

EQUIVALENTS

The present disclosure provides among other things compositions and methods for treating multiple sclerosis and their complications. While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the systems

and methods herein will become apparent to those skilled in the art upon review of this specification. The full scope of the claimed systems and methods should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.


INCORPORATION BY REFERENCE

All publications and patents mentioned herein, including those items listed above, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

44

What is claimed is:

1. A compound of Formula I:




O,O'-(3-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl)oxy)propane-1,2-diyl)dimethyl difumarate

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, which is formulated for delivery to a subject by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

4. A compound of Formula II:



O,O'-(3-(((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenyl)oxy)propane-1,2-diyl)dimethyl difumarate

5. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5, which is formulated for delivery to a subject by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.

* * * * *